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The methodology and application of Mendelian randomization to study causal mechanisms in health and 
disease has developed dramatically over the last decade. New methods, large-scale genome-wide analyses, 
molecular epigenetics, and other new -omics technologies are all providing exceptional opportunities for the 
exploitation of Mendelian randomization approaches to understand causes of complex traits and disease 
outcomes. This research has the potential to identify new approaches for the prevention and treatment of 
common conditions. 
 
The origins of what is now termed “Mendelian randomization” (Figure 1, see caption for assumptions) can 
be traced back over half a century
1
, although the first extended presentation of the principles was in this 
journal just over a decade ago
2
. Since then it has become a widely utilized methodology, with publications 
covering many branches of biomarker
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, behavioural
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, and infectious disease
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epidemiology. Mendelian randomization studies with clear implications for pharmacotherapeutics are also 
becoming commonplace
19
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21
, and applications to social science and to economics (the field in which the 
statistical technique of instrumental variables analysis central to Mendelian randomization was initially 
conceived
22
) are being developed
23
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.  
 
Methodological advances 
 
Over the past few years, several methodological advances have been made. The basic assumption – that 
genetic variants which can proxy for a potentially modifiable exposure are essentially unrelated to 
confounding factors – has been demonstrated to have widespread plausibility25. The connection between the 
standard Mendelian randomization experiment and the theory of instrumental variables has been elaborated 
upon
26
 
27
. Extensions to use multiple genetic variants for increasing power and investigating the influence of 
pleiotropy have been theorized
28
 and implemented
29
 
30
 
31
 
32
. Bidirectional Mendelian randomization for 
informing the direction of causal effects has been exemplified
33
 
34
 and extended to consider more complex 
networks 
35
. Methods for the estimation of non-linear causal effects have been proposed
36
 
37
.  Causal effects 
of related phenotypes with common genetic predictors in a multivariable analysis framework have been 
estimated
38
 
39
. Factorial Mendelian randomization to investigate the combined effect of treatments with 
separate genetic proxies has been undertaken 
40
. Sensitivity analyses for investigating the biasing effects of 
pleiotropy have been developed 
41
 
42
. Extensions to consider gene-by-environment interactions have been 
outlined and applied
43
 
44
 
45
. The integration of epigenetic profiles as an intermediate phenotype has been 
proposed
46
 
47
 and implemented
48
 
49
. The development of Mendelian randomization into the hypothesis-free 
resolution of causal directions in correlated networks has been outlined
50
. In summary, methodological 
development has been undertaken in response to the challenges of new substantive applied questions and 
25 
 
increasingly detailed genetic data. This development has enabled (and continues to enable) more 
sophisticated questions to be answered using the framework of Mendelian randomization. 
 
Mendelian randomization in the post-GWAS era 
 
Initial applications of Mendelian randomization generally incorporated a single genetic variant, and assessed 
the causal relationship of the modifiable intermediate phenotype on the outcome in a single sample. The 
proliferation of genome-wide association study (GWAS) data, and in particular publicly available GWAS 
data 
51
 (such as summary genetic associations with coronary artery disease in over 60 000 cases and 130 000 
controls from the CARDIoGRAMplusC4D consortium
52
) provides opportunities to extend this via the use of: 
 
1) Increased sample sizes. Consortia with GWAS data on large sample sizes are available for many 
phenotypic traits and disease outcomes. This increases the power of Mendelian randomization 
investigations
53
. 
 
2) Multiple genetic variants. For many intermediate phenotypes investigated in Mendelian 
randomization studies, GWAS investigations have been able to identify multiple genetic variants 
contributing to variation in the phenotype. Again, this increases the power of Mendelian 
randomization investigations
54
. 
 
3) Two-sample Mendelian randomization. The ideal context for the precise estimation of genetic 
associations with modifiable intermediate phenotypes is population-based cohort studies. In contrast, 
the ideal context for the precise estimation of genetic associations with disease outcomes is case-
control studies. Two-sample Mendelian randomization is a design strategy whereby genetic 
associations with the phenotype and with the outcome are taken from separate samples
55
. Provided 
that the samples come from the same underlying population (for example, the same ethnicity), valid 
causal estimates can be obtained even if concomitant data on the genetic variants, intermediate 
phenotype, and outcome are not available for any individuals. Moreover, such estimates can be 
obtained from summarized data rather than individual-level data 
56
 
57
. This allows the efficient 
evaluation of causal effects in large sample sizes without requiring sharing of individual-level data. 
 
As it is not required for the phenotype and outcome in two-sample Mendelian randomization to be 
estimated on the same individuals, genetic associations with the phenotype and outcome can be 
taken from large consortia, thus potentially greatly increasing power compared with a one-sample 
Mendelian randomization analysis
51
. 
 
Over the last decade, the heritability of many complex traits has been explored using GWAS. In general, 
common genetic variants have small effects on complex traits. In the recently completed UK10K study 
26 
 
(www.uk10k.org), novel genetic variants with relatively large phenotypic effects were observed
58
. However, 
large effect sizes seemed to be confined to the rarest detectable signals and, for the most part, effects 
attributable to common genetic variants were small. This is rather disappointing from the viewpoint of 
developing predictive tools for even highly heritable traits. Studies like UK10K assessing the genetic 
architecture of complex traits more thoroughly through sequencing suggest that, for complex traits, this 
picture is unlikely to change. But even variants with modest effect sizes provide opportunities for the 
investigation of potential novel causal pathways using Mendelian randomization, particularly given the 
development of novel statistical tools for detecting and adjusting for pleiotropy from multiple genetic 
variants
41
. 
 
The promise of –omics 
 
Mendelian randomization studies have generally focused on a limited number of intermediate phenotypes, 
but recent applications of omic technologies into large scale population based studies present new 
opportunities for identifying novel predictive biomarkers and causal links between established phenotypes 
and disease outcomes
47
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63
.  Both metabolomics and DNA methylation data are increasingly being 
exploited
49
 
64
.  
 
Metabolomic data, representing multiple metabolic pathways in systemic metabolism, can be quantified by 
targeted mass spectroscopy or by proton nuclear magnetic resonance spectroscopy. With this, it has been 
possible to examine the causal role of risk factors such as body mass index (BMI) in the formation of 
metabolomic profiles and thus to consider the finer aetiology of possible disease effects
65
. Furthermore, 
many metabolites have substantial heritability and robust genetic variant associations have already been 
identified 
66
 
67
. Metabolite profiles have proved useful in the prediction of cardiometabolic disease 
68
 
69
, 
although their role as modifiable targets for intervention or causal mediators of disease risk is unclear
49
. The 
availability of genetic instruments for many metabolites provides opportunities to assess the causal effects of 
metabolites on disease risk. Both bi-directional (see above) and hypothesis-generating (see below) 
applications of Mendelian randomisation are likely to be useful in exploiting these data.  
 
Methylation of DNA is a partially stable mechanism for gene regulation, occurring from the earliest stages of 
development onwards, under genetic, environmental and stochastic influences
70
. In a similar way to 
metabolomic data, the availability of large collections of genome-wide epigenetic data marks presents a 
valuable opportunity to consider the role of gene regulation in the aetiology of complex disease. In this case, 
methylation related genetic variants (mQTLs) are used as proxy markers of DNA regulatory variation, which 
may be causally implicated in diseases.  A theoretical framework for this work has been developed
46
 
71
 and 
applied
48
 
49
. (Figure 2)   
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As well as being potential targets for intervention, both metabolomic 
72
 
73
 and methylation data may serve as 
indicators of exposure to difficult-to-measure intermediate phenotypes. In the case of DNA methylation data 
in particular, these could provide proxy measures of long term
74
 or critical period exposure
75
 
76
 that could 
otherwise not be assessed on large population samples.   
 
Taxonomy of Mendelian randomization investigations 
 
Limitations in our understanding of genetic variants used in Mendelian randomization has led to suggestions 
that evidence from Mendelian randomization studies in informal evidence synthesis should be down-
weighted 
77
 
78
 
79
. However, not all applications of Mendelian randomization are the same in terms of their 
aims, procedures and quality of evidence generated.  We provide a taxonomy of Mendelian randomization 
investigations into three broad categories, based largely on the nature of the intermediate phenotype 
evaluated, and the biological plausibility of the genetic variants for use in assessing causal effects. These 
categories are presented separately but form a spectrum of evidence quality, as some investigations will not 
fall neatly into a single category. 
 
1. Validation of potential drug targets 
 
Some phenotypes have a genetic aetiology dominated by a relatively small number of key coding or 
functionally relevant loci (such as C-reactive protein 
3
, interleukin-6 
19 20
, lipoprotein-associated 
phospholipase A2
80
, or secretory phospholipase A2 
81
 , bilirubin 
82
, uric acid 
83
). Mendelian randomization 
investigations conducted using a small number of genetic variants in a single gene region having clear 
biological links to the intermediate phenotype provide the closest parallels to a randomized trial 
84
. These are 
the most plausible Mendelian randomization investigations, in terms of the validity of the instrumental 
variable assumptions that the variants are specific proxies for the phenotype, as well as providing evidence to 
aid the prioritization and development of pharmacological interventions which have a reasonable likelihood 
of producing health benefits
85
. This type of Mendelian randomization experiment mirrors the potential 
effects of a drug acting on the same pathway. Such applications have advantages for pharmaceutical 
companies in prioritizing drugs for clinical trials, and for investigating unintended consequences of drugs 
(both for drug repositioning and for investigating safety signals). 
 
There are several examples of Mendelian randomization investigations relevant to pharmacological 
investigations.  Drugs to inhibit C-reactive protein were not developed further after Mendelian 
randomization experiments demonstrated no causal role of C-reactive protein in cardiovascular disease 
86
 
3
. 
In contrast, interleukin-6 receptor can be blocked by a monoclonal antibody (tocilizumab) which was 
developed for the treatment of rheumatoid arthritis. A variant in the IL6R gene region shows an association 
with coronary heart disease risk 
87
 
88
, so consequently tocilizumab would be worthwhile taking forward into 
trials for cardiovascular risk prevention
89
. As another example, statins are associated with an increased risk 
28 
 
of type 2 diabetes. A Mendelian randomization study using genetic variants coding for HMGCoA reductase 
(the protein target that is inhibited by statins) demonstrated that these variants were associated with an 
increase in type 2 diabetes
90
 
91
. The inference from these findings is that attempts to make statins more 
specific and thereby reduce off -target effects will not avoid the increased risk of the diabetes. Genetic 
variants in the CETP gene region have been used as proxies for cholesterylester transfer protein (CETP) 
inhibitors, such as dalcetrapib
92
. These drugs are developed to raise high-density lipoprotein cholesterol 
levels. Variants in the CETP region have shown null associations with coronary artery disease risk
21
, 
although null associations with blood pressure suggest that the blood pressure-increasing effect of 
torcetrapib
93
 is an off-target effect rather than a downstream consequence of CETP inhibition
94
. 
 
A recent investigation to assess the impact of interleukin-1 inhibition (e.g. by use of the drug anakinra, which 
is beneficial in rheumatoid arthritis) on cardio-metabolic disorders found that genetic variants which proxy 
the effects of sustained dual interleukin-1α/β inhibition were associated with an increased risk of 
cardiovascular diseases 
95
. Two notable aspects of this investigation are the use of positive control variables, 
and the consideration of multiple outcomes. Clinical trials of anakinra show decreases in C-reactive protein 
and interleukin-6 levels that are also predicted by the associations of the genetic variants. The concordant 
associations with these positive controls increase the plausibility that the genetic variants are good proxies 
for the pharmacological intervention. The investigation of large numbers of outcomes, made practical by 
publically-available GWAS data, enables both the search for potential causal mediators of disease risk (in 
this case, proatherogenic lipids), and drug repositioning. Here, rather than finding another disease outcome 
that may be beneficially treated by anakinra, an important safety signal was discovered. 
 
2. Investigation of complex intermediate phenotypes 
 
Many intermediate phenotypes are not regulated by single metabolic pathways but are influenced by multiple 
genetic variants. Examples of multifactorial and polygenic risk factors include body mass index 
96
, height 
97
, 
and blood pressure 
56
.  In these situations, Mendelian randomization investigations often proceed in a 
different manner, and on the basis of a large number of genetic variants in different gene regions. These 
variants may be discovered in GWAS investigations and the biological pathways linking each variant to the 
intermediate phenotype may be unknown. Clearly, the formal instrumental variable assumptions that the only 
causal pathway from the genetic variants to the outcome passes via the phenotype of interest are rarely 
satisfied 
98
. Plausibility of a causal effect can be increased by empirical evidence that the genetic variants are 
not associated with measured confounders, as well as by demonstrating consistency and directional 
concordance of the causal estimate across genetic variants in multiple gene regions with different biological 
effects on the same phenotype. If many different independent genetic variants all suggest the same direction 
of causal effect, and if the overall statistical result is not dependent on one or two variants, then a causal 
conclusion is most plausible
50
. However, the associations of genetic variants with unmeasured or unknown 
confounders cannot be assessed, and so the instrumental variable assumptions are not fully testable. 
29 
 
Additionally, even if a genetic variant is associated with a measured covariate, it is not possible to tell 
empirically whether this association is a (horizontally) pleiotropic effect of the genetic variant (hence a 
violation of the assumptions), or an effect of the intermediate phenotype (a mediated, or vertically pleiotropic 
effect). In the latter case, provided that the only causal pathway from the genetic variant to the outcome is via 
the intermediate phenotype, the instrumental variable assumptions are not violated. 
 
In these cases, the aim of a Mendelian randomization investigation is not only to give a definitive answer as 
to whether the intermediate phenotype is causal or not, but also to investigate mechanisms linking the 
phenotype to the outcome. Particularly for phenotypes such as adult height, which is not readily modifiable, 
the findings of the analysis usually go beyond a simple instrumental variable analysis, and investigate 
potential causal pathways. 
 
3. Hypothesis-generating investigations 
 
A final category of analyses (which some may feel are not true Mendelian randomization analyses) are 
termed “hypothesis-generating investigations”. As with GWAS studies, these are undertaken particularly for 
intermediate phenotypes that do not have strong known genetic determinants, such as educational attainment 
99
 
100
. Automated analyses of associations between a range of risk factors and outcomes have been 
undertaken using whole genome scores 
101
 and using summarized data from across the whole genome 
102
, to 
investigate whether common genetic predictors correlate with phenotypic and outcome traits. Such 
investigations have given mixed results, and should be regarded as hypothesis-generating rather than 
assessments of causation. Nonetheless, they represent a natural extension to the methods of Mendelian 
randomization to obtain more speculative, but potentially findings with greater statistical power if the genetic 
predictors explain more variation in the phenotype. To this end, the application of automated two-sample 
Mendelian randomization in a hypothesis-generating approach is likely to expand rapidly the capacity of 
conventional epidemiology to generate plausible hypotheses. In this case, derived genetic instruments may 
be exported to existing, large, GWAS collections of any disease or outcome and employed to give estimates 
of the causal implications of exposure to novel modifiable risk factors. This would yield a potential return on 
the large collections of genetic variant data in the GWAS community which are, as yet, underutilised.  
 
In this themed issue of the journal we have published both methodological developments and substantive 
findings from many research groups.  Methodology for improving quality of reporting
103
, bias detection due 
to invalid instruments
41
, and mediation in causal pathways
35
 are covered.  The effects of a wide range of 
intermediate phenotypes on disease outcomes using genetic instruments are also examined.  These range 
from tobacco (smoking does lower body weight)
104
, coffee
105
, milk
106
 and alcohol
107
 intakes, obesity
108
 
109
, 
vitamin D
110
 and testosterone
111
 
112
.  These analyses using genetic instruments provide an alternative means 
of examining causal associations, particularly in circumstances where associations are likely to be heavily 
confounded and randomized experiments are not feasible. 
30 
 
 
Caution and conclusion 
 
Potential limitations of the Mendelian randomization strategy were discussed extensively in its initial formal 
presentation
2 
and have been reiterated elsewhere
113
 
114
 
115
 
116
. Largely as a function of the potentially 
overwhelming collection of genetic variants presented to the epidemiologist looking to practice Mendelian 
randomization, the potential to fall into one of a series of analytical traps has been increased. Power, linkage 
disequilibrium, pleiotropy, canalization and population stratification have all been recognised as potential 
flaws in the Mendelian randomization approach as methods have been developed. Whilst avoidance 
strategies for these limitations are now really beginning to appear, further limitations are being realised. In 
circumstances where we are less likely to have well-characterised, candidate driven, and biologically 
understood genetic variants as instruments, it is tempting to use the totality of available variants in an 
analysis, for example in a genetic risk score approach 
117
. Whilst it is attractive at the outset to amalgamate 
genetic variants into comprehensive genetic scores which have the potential to increase variance in the 
phenotype explained (and thus increase power) 
118
, it is increasingly clear is that where these scores are not 
understood completely, the potential for inferential complication is greater now than ever. 
 
Using the example of educational attainment, large-scale GWAS meta-analysis has successfully identified 
genetic variants reliably correlated with education 
99
. However, these signals represent a small fraction of the 
total variability in educational attainment 
100
. Genome-wide predictors will enhance the power of a 
Mendelian randomization analysis, with genetic scores including all variants (even those not associated at a 
conventional level of significance) explaining around 3% of the variance. (See Figure 3). However, as a 
result of the combined impact of linkage disequilibrium, genetic contributions from many different 
biological pathways, and the possible biasing effects of pleiotropy, the use of such a genome-wide estimator 
may sadly produce effect estimates which suffer the similar limitations as a more conventional, 
observational, estimate. 
 
The next decade will see a deeper understanding of the properties of genetic variants which will be is crucial 
to the appropriate implementation and interpretation of Mendelian randomization analyses. Over the last 
decade, Mendelian randomization has provided a novel and flexible paradigm to understand the causal nature 
of associations between modifiable risk factors and common diseases. Mendelian randomization has made 
use of the massive investment in human genetic research, focusing on causal mechanisms that have the 
promise of identifying worthwhile targets for pharmacological research and for preventive public health 
interventions that are already making a difference and will continue to do so in the coming decade. 
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Figure 1. Mendelian randomization: using genetic variants as instrumental variables to establish whether an 
exposure is causally related to a disease or trait. 
 
 
 
(A) The genotype acts as an instrumental variable if: i) it is associated with the exposure, ii) it is independent of measured or 
unmeasured confounders, and iii) it can only influence that outcome via the causal effect of the exposure. 
  
(B) Under the instrumental variable assumptions, the lack of association between the C-reactive protein genotype and disease risk 
indicates that C-reactive protein is not a causal risk factor for ischaemic heart disease. An association between the genotype and 
disease outcome would indicate a causal relationship of the exposure on the outcome. 
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Figure 2. Two-step and integrated two-step/two-sample approaches in the application of Mendelian 
randomization to methylation data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A - Two-step Mendelian randomization: Genetic variants can be used as instrumental variables in a two-step framework to establish 
whether metabolites are on the casual pathway between exposure and disease. First, a genetic variant (SNP 1) associated with the 
exposure of interest to assess the causal impact of the exposure on an intermediate trait (in this case tissue specific methylation). 
Second, a different genetic variant (SNP 2) associated with the intermediate trait (and not associated with the exposure) is used to 
assess the causal impact of the intermediate trait on the outcome. 
 
B - Two-sample/two-step Mendelian randomization: We consider tissue specific DNA methylation as a potentially causal 
intermediate phenotype. In a potentially smaller first sample the association of the exposure to DNA methylation is established using 
a Mendelian randomization approach (with the exposure-related SNP 1). A genetic variant associated with the same methylation 
difference but not related to the exposure is identified (SNP 2). In a potentially larger second sample the exposure is shown to 
influence the outcome through the use of SNP 1, and the exposure-related methylation is shown to influence the outcome through the 
use of SNP 2. 
 
(Adapted with permission from Davey Smith G, Hemani G.  Mendelian randomization: genetic anchors for causal inference in 
epidemiological studies.  Hum Mol Genet 2014;23:r89-98 doi: 10.1093/hmg/ddu328.) 
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Figure 3. Estimates of variance explained by common genetic variants for educational attainment for 
differing portions of the genetic association spectrum.  
 
 
 
 
 
 
 
 
 
 
 
Image adapted from Rietveld et al, Science 2013. Light grey lines (solid and mixed) show results from regressions of the number of 
years in education (EduYears) on linear polygenic scores in a set of unrelated individuals from two independent epidemiological 
studies; QIMR (n = 3526 – light grey) and STR (n = 6770 – dark grey). Solid lines indicate results from regressions of EduYears on 
linear polygenic derived from the genomewide association analysis of years in education and dashed lines the genomewide 
association analysis of the presence or absence of college education.  
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